GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nipro Corp (OTCPK:NPRRF) » Definitions » COGS-to-Revenue

Nipro (NPRRF) COGS-to-Revenue : 0.70 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Nipro COGS-to-Revenue?

Nipro's Cost of Goods Sold for the three months ended in Dec. 2023 was $743 Mil. Its Revenue for the three months ended in Dec. 2023 was $1,065 Mil.

Nipro's COGS to Revenue for the three months ended in Dec. 2023 was 0.70.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Nipro's Gross Margin % for the three months ended in Dec. 2023 was 30.19%.


Nipro COGS-to-Revenue Historical Data

The historical data trend for Nipro's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nipro COGS-to-Revenue Chart

Nipro Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.70 0.70 0.70 0.71

Nipro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.69 0.71 0.70 0.73

Nipro COGS-to-Revenue Calculation

Nipro's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2773.121 / 3916.637
=0.71

Nipro's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=743.165 / 1064.512
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nipro  (OTCPK:NPRRF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Nipro's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 743.165 / 1064.512
=30.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Nipro COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nipro's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nipro (NPRRF) Business Description

Traded in Other Exchanges
Address
3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.

Nipro (NPRRF) Headlines

No Headlines